Gastric precancerous conditions

There are 3 papers on gastric precancerous conditions in aging research: 2 trials and 1 observational study in people. The newest story, Nov 1, 2026: “Eflornithine may lower a DNA damage marker in stomach lesions”.

Disease

3 papers study it1 finding

See all 3 papers on gastric precancerous conditions

“Gastric precancerous conditions were identified in 46.9% of screened individuals”
Opportunistic Gastric Cancer Endoscopic Screening Integrated Into Population-Based Colorectal Cancer Screening: A Retrospective Economic Cost-Comparison StudyHelicobacter2026doi:10.1111/hel.70161
  • Human trial2
  • Humans1

Associations

1

Esophagogastroduodenoscopy

upin humans1+47%

1 study
  1. Esophagogastroduodenoscopy is associated with gastric precancerous conditions in humans during colonoscopy within colorectal cancer screening (46.9%).

    Humansduring colonoscopy within colorectal cancer screeningstomachone-timen = 377

More on Esophagogastroduodenoscopy

Trial sponsors

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 1Nov 2026: 03 papers in 12 months
Cancer Prevention Research

Eflornithine may lower a DNA damage marker in stomach lesions

Between months 18 and 24, after treatment ended, DNA damage marker scores fell 18.3 points with eflornithine versus 1.6 with placebo.Between months 18 and 24, after treatment ended, DNA damage marker scores fell 18.3 points with eflornithine versus 1.6 with placebo.

Randomized trial · 55 peopleInterventions